SEI Investments’s Stemline Therapeutics, Inc. STML Stock Holding History

SEI Investments’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-130	Closed	-$2K	–	3703
2018 Q2	$2K	Hold	130	–	–	﹤0.01%	3410
2018 Q1	$2K	Hold	130	–	–	﹤0.01%	3286
2017 Q4	$2K	Hold	130	–	–	﹤0.01%	3161
2017 Q3	$1K	Sell	130 -870	-87%	-$8.18K	﹤0.01%	3150
2017 Q2	$9K	Buy	+1,000	New	+$8.34K	﹤0.01%	2622

Other funds holding STML

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LSC

Lyon Street Capital Sausalito, California $67M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SEI Investments's STML Position: Q3 2018 in Review

SEI Investments sold out of Stemline Therapeutics, Inc. (STML) in Q3 2018, closing a stake of 130 shares — an estimated $2K sold.

SEI Investments first reported a position in STML in Q2 2017 and held it in 5 quarters. The position peaked at $9K in Q2 2017. 90 funds tracked by Wall St. Rank hold STML as of Q3 2018.

SEI Investments reported no remaining Stemline Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
SEI Investments sold 130 Stemline Therapeutics, Inc. shares in Q3 2018, an estimated $2K.
SEI Investments first reported a position in Stemline Therapeutics, Inc. in Q2 2017 and held it in 5 quarters.
SEI Investments's Stemline Therapeutics, Inc. position peaked at $9K in Q2 2017.
90 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q3 2018.

Based on SEI Investments's 13F filing for Q3 2018, filed 8 Nov 2018.